in order to determine whether combination chemotherapy offered any advantage over single-agent therapy in cases of metastatic non-small cell bronchogenic carcinoma , we performed a randomized study in 56 patients comparing combination chemotherapy ( cyclophosphamide , doxorubicin , methotrexate , procarbazine , leucovorin -- camp-l ) with a regimen in which the same drugs were given sequentially ( methotrexate/leucovorin followed by cyclophosphamide/doxorubicin at progression ) .
C0010583
cyclophosphamide
C0050385
cyclophosphamide/doxorubicin